Ad
Search
Generic filters
Filter by content type
Taxonomy terms

BIVI – BioVie Inc

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.75

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 10.5

Low: 7

High: 14

Total Analysts: 3

Company Profile

BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of drug therapies for liver disease. The Company is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The Company is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The Company is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses